PMID- 15891397
OWN - NLM
STAT- MEDLINE
DCOM- 20050816
LR  - 20191026
IS  - 0957-9672 (Print)
IS  - 0957-9672 (Linking)
VI  - 16
IP  - 3
DP  - 2005 Jun
TI  - High-density lipoproteins as therapeutic targets.
PG  - 345-9
AB  - PURPOSE OF REVIEW: The concentration of cholesterol in HDL is an inverse 
      predictor of future cardiovascular disease, with evidence mounting that therapies 
      that increase HDL concentration are antiatherogenic. The best known 
      antiatherogenic function of HDL particles relates to their ability to promote the 
      efflux of cholesterol from cells. However, they also have antioxidant, 
      antiinflammatory and antithrombotic properties. RECENT FINDINGS: The past year 
      has seen the publication of several papers that highlight a potential major 
      protective role of HDL in states of acute inflammation. Papers showing extremely 
      promising results using novel inhibitors of cholesteryl ester transfer protein as 
      HDL-raising agents have also appeared. Finally, the discovery that ATP-binding 
      cassette transporter G1 (ABCG1) transports cell cholesterol to large HDL 
      particles in the extracellular space has largely reconciled apparent 
      inconsistencies between basic research indicating that small, pre-beta-migrating 
      HDL particles are the antiatherogenic components of HDL and epidemiological 
      research that implicates larger HDL particles as the protective fraction. 
      SUMMARY: The finding that ABCG1 promotes the efflux of cholesterol from cells to 
      large HDL particles also provides powerful circumstantial evidence that 
      cholesteryl ester transfer protein inhibition (which increases HDL size) may 
      enhance, rather than reduce, cholesterol efflux, and thus inhibit the development 
      of atherosclerosis.
FAU - Nicholls, Stephen J
AU  - Nicholls SJ
AD  - The Heart Research Institute, Sydney, Australia.
FAU - Rye, Kerry-Anne
AU  - Rye KA
FAU - Barter, Philip J
AU  - Barter PJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Lipidol
JT  - Current opinion in lipidology
JID - 9010000
RN  - 0 (ABCG1 protein, human)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily G, Member 1)
RN  - 0 (ATP-Binding Cassette Transporters)
RN  - 0 (Cholesterol, HDL)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily G, Member 1
MH  - ATP-Binding Cassette Transporters/*physiology
MH  - Animals
MH  - Arteriosclerosis/*physiopathology/prevention & control
MH  - Cholesterol/metabolism
MH  - Cholesterol, HDL/metabolism/*physiology/therapeutic use
MH  - Humans
MH  - Inflammation/*immunology
MH  - Infusions, Intravenous
MH  - Rabbits
RF  - 32
EDAT- 2005/05/14 09:00
MHDA- 2005/08/17 09:00
CRDT- 2005/05/14 09:00
PHST- 2005/05/14 09:00 [pubmed]
PHST- 2005/08/17 09:00 [medline]
PHST- 2005/05/14 09:00 [entrez]
AID - 00041433-200506000-00013 [pii]
AID - 10.1097/01.mol.0000169356.58513.25 [doi]
PST - ppublish
SO  - Curr Opin Lipidol. 2005 Jun;16(3):345-9. doi: 10.1097/01.mol.0000169356.58513.25.